EFFECTS OF METABOLIC DRUG ELTACINE ON CLINICAL, FUNCTIONAL AND BIOCHEMICAL INDICES IN PATIENTS WITH CHRONIC HEART FAILURE
https://doi.org/10.20996/1819-6446-2007-3-1-33-36
Abstract
Aim. To study clinical efficacy of a new domestic metabolic drug Eltacine in patients with chronic heart failure (CHF).
Material and methods. 134 patients with CHF of I-III functional classes were randomized in two parallel groups of patients receiving Eltacine or placebo additionally to standard therapy. Common clinical and laboratory investigations were used as well as 6-minute-walking test and Echocardiography. Besides Holter monitoring with determination of heart rate variability, peroxidal oxidation of lipids (POL) and cell anti-oxidant protection were implemented.
Results. Eltacine increased in tolerance to physical burden, improved cardiac haemodynamics, parameters of POL and cell anti-oxidant protection, improved the patient quality of life.
Conclusion. The efficacy and safety of Eltacine as metabolic and antioxidant therapy was shown in patients with CHF.
About the Authors
R. M. Zaslavskaya
City clinical Hospital N 60, Institute of cytochemistry and molecular pharmacology, Moscow
Russian Federation
Russian Federation
G. V. Lilitsa
City clinical Hospital N 60, Institute of cytochemistry and molecular pharmacology, Moscow
Russian Federation
Russian Federation
Ye. V. Kalinina
City clinical Hospital N 60, Institute of cytochemistry and molecular pharmacology, Moscow
Russian Federation
Russian Federation
I. A. Komissarova
City clinical Hospital N 60, Institute of cytochemistry and molecular pharmacology, Moscow
Russian Federation
Russian Federation
L. N. Maximova
City clinical Hospital N 60, Institute of cytochemistry and molecular pharmacology, Moscow
Russian Federation
Russian Federation
References
1. Жданов Г.Г., Соколов И.М. Некоторые аспекты тканевой гипоксии при остром инфаркте миокарда. Вестник интенсивной терапии. 1995: 2; 23-26.
2. Коган А.Х., Ершов В.П. О механизме усиления свободнорадикальных процессов у больных ишемической болезнью сердца, стенокардией в зависимости от возраста. Терапевтический архив. 1994; 4; 9-11.
3. Конская Н.В. Диагностическая значимость определения малонового диальдегида и ЛПВП крови при ИБС. Тезисы докладов Всесоюзного симпозиума «Актуальные вопросы кардиологии», Томск, 1989; 58-60.
4. Кратнов А.Е. Атеросклероз и ишемическая болезнь сердца: роль окислительного стресса. Ярославль; Издательство ЯРГУ; 2003; 196.
5. Ланкин В.З., Тихадзе А.К., Беленков Ю.Н. Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы. Кардиология; 2000; 7: 48-57.
Review
For citations:
Zaslavskaya R.M., Lilitsa G.V., Kalinina Ye.V., Komissarova I.A., Maximova L.N. EFFECTS OF METABOLIC DRUG ELTACINE ON CLINICAL, FUNCTIONAL AND BIOCHEMICAL INDICES IN PATIENTS WITH CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2007;3(1):33-36. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-1-33-36
Views:
1978
Email this article 